FrancophonIA/ELRC3.0 huggingface dataset:
English: When normalised to body surface area, the exposure to rivastigmine and its metabolites was approximately equivalent to the maximum recommended human dose of 12 mg/day; however, when compared to the maximum human dose, a multiple of approximately 6-fold was achieved in animals.
Maltese: Meta ġew imqabbla skond l-erja tas-superfiċje tal-ġisem, lespożizzjoni għal rivastigmine u l-metaboli tiegħu kienet bejn wieħed u ieħor ekwivalenti għad-doża massima rrakkomandata ta' 12 mg kuljum; madankollu, meta mqabbla mad-doża massima fil bniedem, livelli ta' bejn wieħed u ieħor 6 darbiet aktar kienu milħuqa fl-annimali.
English: Rivastigmine is rapidly and extensively metabolised (half-life in plasma approximately 1 hour), primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite.
Maltese: Bijotrasformazzjoni Rivastigmine huwa metabolizzat malajr u b'mod estensiv f'metabolu decarbamylated (half-life fil plasma, madwar siegħa), l-aktar b'idroliżi immedjata minn cholinesterase.
English: Each capsule contains 3 mg of rivastigmine (as hydrogen tartrate).
Maltese: Kull kapsula fiha 3 mg ta' rivastigmine (bħala hydrogen tartrate).
English: • Aggression, feeling restless
Maltese: Aggressjoni, nuqqas ta' kwiet
English: As a cholinesterase inhibitor, rivastigmine may exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia.
Maltese: Bħala sustanza li tinibixxi cholinesterase, rivastigmine jista' jeżaġera l-effetti rilassanti tal-muskoli tat tip succinylcholine waqt il-loppju.
English: Mean baseline ± SD Mean change at 24 weeks ± SD
Maltese: 24 ġimgħa ± SD
English: • Unusually slow movements or movements you cannot control
Maltese: • Movimenti bil-mod mhux tas-soltu jew movimenti li ma jistgħux jikkontrollawhom
English: Use of scopolamine as an antidote is not recommended.
Maltese: L-użu ta' scopolamine bħala antidotu mhux irrakkomandat.
English: Movement disorder Bradykinesia
Maltese: Disturbi fil-metaboliżmu u nnutrizzjoni
English: In pregnant animals, rivastigmine and/or metabolites crossed the placenta.
Maltese: F'annimali waqt it-tqala, rivastigmine u/jew il-metaboliti tiegħu qasmu l-plaċenta.
English: Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10-24.
Maltese: Il-pazjenti involuti f'dan l-istudju kellhom punteġġ ta' MMSE (Eżami Żgħir ta' l-Istat Mentali) ta' 10-24.
English: Thus, rivastigmine may have an ameliorative effect on cholinergic-mediated cognitive deficits in dementia associated with Alzheimer's disease and Parkinson's disease.
Maltese: jkollu effett li jtejjeb id-diffikultajiet ta' għarfien li jkunu medjati b'mod kolinerġiku u li huma assoċjati mal-marda ta' Alzheimer u l-marda ta' Parkinson.
English: • Headache
Maltese: • • Ansjetà
English: Quinoline yellow WS dye (E104) Purified water
Maltese: (E104) u ilma purifikat.
English: Some cases of severe vomiting were associated with oesophageal rupture (see section 4.4).
Maltese: Xi każijiet ta' rimettar sever kienu assoċjati ma' tiċrit ta' l esofagu (ara sezzjoni 4.4).
English: The secondary definition of response required a 4-point or greater improvement on the ADAS-Cog, no worsening on the CIBIC-Plus, and no worsening on the PDS.
Maltese: Definizzjoni sekondarja ta' rispons kienet teħtieġ titjib ta' 4 punti jew aktar fl-ADAS-Cog, li l-iskala tas-CIBIC-Plus u dik tal
English: Nervous system disorders
Maltese: Disturbi fis-sistema nervuża Komuni ħafna
English: Hepatobiliary disorders
Maltese: EFFIKAĊI TAL-PRODOTT MEDIĊINALI
English: The results for clinically relevant responders pooled from two flexible dose studies out of the three pivotal 26-week multicentre studies in patients with mild-to-moderately severe Alzheimer's Dementia, are provided in Table 4 below.
Maltese: Ir-riżultati ta' pazjenti li wrew titjib klinikament rilevanti, li kienu miġbura minn żewġ studji bid-doża flessibbli minn 3 studji multiċentriċi pivotali ta' 26 ġimgħa fuq pazjenti li kienu jbatu minn dimenzja ta' Alzheimer ta' severità ħafifa għal moderatament severa, jinsabu f'Tabella 4 hawn taħt.
English: - Capsule fill: - Microcrystaline cellulose
Maltese: Kapsula ibsin
English: Uncommon (may affect up to 1 in 100 people) • Hyperactivity (high level of activity, restlessness)
Maltese: • Attività eċċessiva (livell għoli ta' attività, irrekitezza)
English: SK-821 04 Bratislava Tel: +421 2 48 200 601
Maltese: SK-821 04 Bratislava
English: EMA/760429/2012 corr. EMEA/H/C/001048
Maltese: EMA/799906/2012 EMEA/H/C/001048
English: The full EPAR for Jalra can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: L-EPAR sħiħ għal Jalra jinstab fis-sit elettroniku tal-Aġenzija ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The active substance in Jalra, vildagliptin, is a dipeptidyl peptidase 4 (DPP-4) inhibitor.
Maltese: Is-sustanza attiva f'Jalra, il-vildagliptin, hija inibitur tad-dipeptidil-peptidażi-4 (DPP-4)..
English: This is a summary of the European public assessment report (EPAR) for Jalra.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Jalra.
English: Jalra is a medicine that contains the active substance vildagliptin.
Maltese: Jalra huwa mediċina li fiha s-sustanza attiva vildagliptin.
English: In adults, the recommended dose of Jalra is:
Maltese: Fl-adulti, id-doża rakkomandata ta' Jalra hija:
English: Why has Jalra been approved?
Maltese: Għaliex ġie approvat Jalra?
English: Four studies compared the effects of Jalra, taken at doses of 50 or 100 mg a day for 24 weeks, with those of placebo, when used as an add-on to existing treatment with metformin (544 patients), pioglitazone (a thiazolidinedione, 463 patients), glimepiride (a sulphonylurea, 515 patients) or insulin (296 patients).
Maltese: Erba' studji qabblu l-effetti ta' Jalra, meħud f'dożi ta' 50 jew 100 mg kuljum għal 24 ġimgħa, ma' dawk tal-plaċebo, meta użat bħala trattament aġġuntiv mat-trattament eżistenti bil-metformina (544 pazjent), bil-pijoglitażonu (tijażolidinedjonu, 463 pazjent), bil-glimepiride (sulfonilurea, 515-il pazjent) jew bl-insulina (296 pazjent).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Jalra on 19 November 2008.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Jalra valida fl-Unjoni Ewropea kollha fid-19 ta' Novembru 2008.
English: The CHMP noted that Jalra was effective as an add-on to metformin, a thiazolidinedione or a sulphonylurea (dual therapy), a sulphonylurea and metformin (triple therapy) or insulin with or without metformin, and concluded that the benefits of the add-on treatment outweigh the risks.
Maltese: Is-CHMP innota li Jalra kien effikaċi bħala trattament aġġuntiv mat-trattament bil-metformina, bittijażolidinedjonu jew bis-sulfonilurea (terapija doppja), bis-sulfonilurea u bil-metformina (terapija tripla) jew bl-insulina bil-metformina jew mingħajrha, u kkonkluda li l-benefiċċji tat-trattament aġġuntiv huma akbar mir-riskji.
English: Five of these studies looked at the effects of Jalra taken alone in a total of 3,644 patients, comparing it with placebo (a dummy treatment), metformin, rosiglitazone (a thiazolidinedione) or or gliclazide (a sulphonylurea).
Maltese: Ħamsa minn dawn l-istudji analizzaw l-effetti ta' Jalra meħud waħdu f'total ta' 3,644 pazjent, u qabbluh ma' plaċebo (trattament finta), mal-metformina, mar-rosiglitażonu (tijażolidinedjonu) jew mal-glikażide (sulfonilurea).
English: With metformin and with pioglitazone, the 100 mg daily dose was more effective than the 50 mg daily dose, with a reduction in HbA1c levels of between 0.8 and 1.0 percentage points.
Maltese: Id-doża ta' kuljum ta' 100 mg meħuda mal-metformina u mal-pijoglitażonu kienet aktar effikaċi mid-doża ta' kuljum ta' 50 mg, tant li rreġistrat tnaqqis bejn 0.8 u 1.0% punti perċentwali fil-livelli tal-HbA1c.
English: Jalra used on its own was effective at reducing levels of HbA1c, but was less effective than the comparator medicines.
Maltese: Jalra użat waħdu kien iżjed effikaċi fit-tnaqqis tal-livelli tal-HbA1c, iżda inqas effikaċi mill-mediċini kumparattivi.
English: Jalra is not recommended for patients who have moderate or severe problems with their kidneys, including those on haemodialysis (a blood clearance technique) with end-stage renal disease.
Maltese: Jalra mhuwiex rakkomandat għal pazjenti bi problemi moderati jew gravi fil-kliewi, inklużi dawk li tkun qed issirilhom emodijaliżi (teknika ta' tisfija tad-demm) b'mard renali fi stat terminali.
English: In combination with metformin and glimepiride, 50 mg Jalra taken twice a day reduced HbA1c levels by 1 percentage point, compared with a reduction of 0.3 percentage points in patients taking placebo.
Maltese: Flimkien mal-metformina u l-glimepiride, 50 mg Jalra meħud darbtejn kuljum naqqsu l-livelli ta' HbA1c b'punt perċentwali wieħed, meta mqabbel ma' tnaqqis ta' 0.3 punti perċentwali f'pazjenti li kienu qed jieħdu l-plaċebo.
English: Patients taking Jalra in addition to insulin, with or without metformin, had a reduction in HbA1c levels of 0.77 percentage points, compared with 0.05 percentage points in patients taking placebo in addition to insulin.
Maltese: Il-pazjenti li kienu qed jieħdu Jalra flimkien malinsulina, bil-metformina jew mingħajrha, kellhom tnaqqis ta' 0.77 punti perċentwali fil-livelli ta' HbA1c, meta mqabbla ma' 0.05 punti perċentwali f'pazjenti li kienu qed jieħdu l-plaċebo flimkien mal-insulina.
English: What is Jalra?
Maltese: Kif jaħdem Jalra?
English: • together with a sulphonylurea and metformin (triple therapy) in patients whose diabetes is not sufficiently controlled by these medicines plus diet and exercise;
Maltese: • flimkien mas-sulfonilurea u l-metformina (terapija tripla) f'pazjenti li d-dijabete tagħhom ma tkunx ikkontrollata biżżejjed b'dawn il-mediċini flimkien mad-dieta u l-eżerċizzju;
English: How has Jalra been studied?
Maltese: Kif ġie studjat Jalra?
English: A further study compared Jalra with placebo as an add-on treatment in 449 patients who were already taking a stable dose of long-acting insulin.
Maltese: Studju ieħor qabbel Jalra mal-plaċebo bħala trattament aġġuntiv f'449 pazjent li kienu diġà qed jirċievu doża stabbli tal-insulina li taħdem fit-tul.
English: In the study comparing Jalra with metformin, significantly better results were seen with metformin: a reduction in HbA1c of 1.5 percentage points after 52 weeks compared with a reduction of around 1 percentage point in patients treated with Jalra.
Maltese: Fl-istudju li qabbel lil Jalra mal-metaformina, il-kura bil-metaformina tat riżultati aħjar b'mod sinifikanti: tnaqqis fil-HbA1c b'1.5 punti perċentwali wara 52 ġimgħa meta mqabbel ma' tnaqqis ta' madwar punt perċentwal wieħed f'pazjenti kkurati b'Jalra.
English: Because vildagliptin has been associated with liver problems, patients should have tests to check their liver function before treatment with Jalra and at regular intervals during treatment.
Maltese: Peress li l-vildagliptin kienet assoċjata ma' problemi fil-fwied, il-pazjenti għandhom jagħmlu testijiet tal-fwied qabel it-trattament b'Jalra u f'intervalli regolari matul it-trattament.
English: Jalra is used to treat type 2 diabetes mellitus.
Maltese: Jalra jintuża fil-kura tad-dijabete mellitu tat-tip 2.
English: When used as an add-on to existing treatment for type 2 diabetes, Jalra was more effective than placebo in reducing HbA1c levels.
Maltese: Meta użat bħala terapija aġġuntiva mat-trattament eżistenti għad-dijabete tat-tip 2, irriżulta li Jalra kien aktar effikaċi minn plaċebo fit-tnaqqis tal-livelli tal-HbA1c.
English: A further study compared Jalra with placebo as an add-on treatment in 318 patients who were already taking metformin and glimepiride.
Maltese: Studju ieħor qabbel Jalra mal-plaċebo bħala trattament aġġuntiv fi 318-il pazjent li kienu diġà qed jirċievu l-metformina u l-glimepiride.
English: Other information about Jalra
Maltese: Kif jintuża Jalra?
English: For the full list of all side effects reported with Jalra, including side effects occurring when Jalra is taken with other antidiabetes medicines, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrapportati bl-użu ta' Jalra, inklużi l-effetti tatteħid ta' Jalra ma' mediċini antidijabetiċi oħrajn, ara l-fuljett ta' tagħrif.
English: Jalra has been studied in eleven main studies involving a total of over 5,000 patients with type 2 diabetes and insufficient control of blood glucose levels.
Maltese: Jalra ġie studjat fi ħdax-il studju prinċipali li kienu jinvolvu total ta' aktar minn 5,000 pazjent li jbatu mid-dijabete tat-tip 2 u b'kontroll insuffiċjenti tal-livelli tal-glukożju fid-demm.
English: The most common side effect with Jalra (seen in between 1 and 10 patients in 100) is dizziness.
Maltese: L-effett sekondarju l-aktar komuni bl-użu ta' Jalra (li deher f'bejn pazjent 1 u 10 minn 100) kien sturdament.
English: The full EPAR for Kaletra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This summary was last updated in 07-2017.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f' 07-2017.
English: HIV is the virus that causes acquired immune deficiency syndrome (AIDS).
Maltese: L-HIV huwa l-virus li jikkawża sindrome ta' immunodefiċjenza akkwiżita (AIDS, acquired immune deficiency syndrome).
English: Other information about Kaletra
Maltese: Informazzjoni oħra dwar Kaletra
English: Kaletra is available as tablets, capsules and oral liquid.
Maltese: Kaletra jiġi bħala pilloli, kapsuli u likwidu orali.
English: This is a summary of the European public assessment report (EPAR) for Kaletra.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta᾽ valutazzjoni (EPAR) għal Kaletra.
English: Side effects are similar in children.
Maltese: L-effetti sekondarji kienu simili fit-tfal.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Kaletra on 20 March 2001.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Kaletra fl-20 ta' Marzu 2001.
English: Both active substances in Kaletra are protease inhibitors: they block an enzyme called protease that is involved in the reproduction of HIV.
Maltese: Iż-żewġ sustanzi attivi f' Kaletra huma inibituri tal-protease: dawn jimblukkaw enzima msejħa protease li hija involuta fir-riproduzzjoni tal-HIV.
English: Kaletra contains two active substances, lopinavir and ritonavir.
Maltese: Kaletra fih żewġ sustanzi attivi, lopinavir u ritonavir.
English: Studies in children from 14 days of age showed between 71% and 85% of patients having very low levels of the virus after 48 weeks of treatment with Kaletra.
Maltese: Studji fit-tfal minn età ta' 14-il jum urew li bejn 71% u 85% tal-pazjenti kellhom livelli baxxi ħafna tal-virus wara 48 ġimgħa ta' kura b' Kaletra.
English: In one study of adults who had not been treated for HIV before, 79% of the patients taking Kaletra (259 out of 326) had very low levels of the virus after 24 weeks, compared with 71% of the patients taking nelfinavir (233 out of 327).
Maltese: Fi studju wieħed ta' adulti li qatt ma kienu ġew ikkurati għall-HIV qabel, 79% tal-pazjenti li kienu qed jieħdu Kaletra (259 minn 326) kellhom livelli baxxi ħafna tal-virus wara 24 ġimgħa, meta mqabbla ma' 71% tal-pazjenti li kienu qed jieħdu nelfinavir (233 minn 327).
English: Why is Kaletra approved?
Maltese: Għaliex ġie approvat Kaletra?
English: Kaletra is effective at reducing HIV viral loads to below 400 copies/ml in the majority of adults and children from 14 days of age.
Maltese: Kaletra huwa effettiv biex inaqqas it-tagħbijiet virali tal-HIV għal inqas minn 400 kopja/ml filmaġġoranza tal-adulti u tat-tfal mill-età ta' 14-il jum.
English: What are the risks associated with Kaletra?
Maltese: X' inhuma r-riskji assoċjati ma' Kaletra?
English: A second adult study in patients who had previously taken a protease inhibitor, 73% of the patients taking Kaletra (43 out of 59) had very low levels of the virus after 16 weeks, compared with 54% of the patients taking the comparator medicines (32 out of 59).
Maltese: Studju ieħor fl-adulti f' pazjenti li preċedentement kienu ħadu inibitur tal-protease, 73% tal-pazjenti li kienu qed jieħdu Kaletra (43 minn 59) kellhom livelli baxxi ħafna tal-virus wara 16-il ġimgħa, meta mqabbla ma' 54% tal-pazjenti li kienu qed jieħdu mediċini komparaturi (32 minn 59).
English: The most common side effects with Kaletra in adults (seen in more than 1 patient in 10) are upper respiratory tract infection (colds), nausea (feeling sick) and diarrhoea.
Maltese: L-effetti sekondarji l-aktar komuni b' Kaletra fl-adulti (li dehru f' aktar minn pazjent 1 minn kull 10) huma infezzjonijiet fil-parti ta' fuq tal-apparat respiratorju (irjiħat), nawżja (tħossok ma tiflaħx) u dijarea.
English: Studies have shown that Kaletra is effective at reducing viral load (the amount of virus found in the blood) to very low levels (below 400 copies/ml).
Maltese: L-istudji wrew li Kaletra huwa effettiv biex inaqqas it-tagħbija virali (l-ammont ta' virus misjub fiddemm) għal livelli baxxi ħafna (inqas minn 400 kopja/ml).
English: Kaletra is an HIV medicine used in combination with other medicines to treat adults and children from over 14 days of age who are infected with HIV-1.
Maltese: Kaletra huwa mediċina kontra l-HIV li tintuża flimkien ma' mediċini oħra biex tikkura adulti u tfal ta' età ta' ' l fuq minn erbatax-il jum li jkunu infettati bl-HIV-1.
English: Kaletra must not be used by patients with severe liver disease or by patients who are taking St John's wort (a herbal preparation used to treat depression) or medicines that are broken down in the same way as Kaletra and are harmful at high levels in the blood.
Maltese: Kaletra m' għandux jintuża minn pazjenti b' mard tal-fwied gravi jew minn pazjenti li jkunu qed jieħdu St John's wort (preparazzjoni erbali li tintuża biex tikkura d-dipressjoni) jew mediċini li jitkissru bl-istess mod bħal Kaletra u li jagħmlu ħsara meta jkunu f' livelli għoljin fid-demm.
English: The medicine is taken once or twice daily in adults, and the dose depends on the type of virus the patient is infected with.
Maltese: Il-mediċina tittieħed darba jew darbtejn kuljum fl-adulti, u d-doża tiddependi mit-tip ta' virus li lpazjent ikun infettat bih.
English: In Kaletra, lopinavir provides the activity against the virus while ritonavir mainly works as a ‘booster' to slow down the rate at which lopinavir is broken down by the liver.
Maltese: attività kontra l-virus waqt li r-ritonavir prinċipalment taħdem bħala ‘buster' biex titnaqqas ir-rata li biha l-lopinavir titkisser mill-fwied.
English: Kaletra does not cure HIV infection or AIDS, but it may hold off damage to the immune system, and the development of infections and diseases associated with AIDS.
Maltese: Kaletra ma jikkurax l-infezzjoni tal-HIV jew l-AIDS, iżda jista' jittardja l-ħsara lis-sistema immunitarja, u l-iżvilupp ta' infezzjonijiet u mard assoċjat mal-AIDS.
English: How does Kaletra work?
Maltese: Kif jintuża Kaletra?
English: The European Medicines Agency (EMA) therefore concluded that the benefits of Kaletra outweigh its risks and recommended that it be given marketing authorisation in the EU.
Maltese: Għaldaqstant, l-Aġenzija Ewropea għall-Mediċini (EMA) ikkonkludiet li l-benefiċċji ta' Kaletra huma akbar mir-riskji tiegħu u rrakkomandat li jingħata awtorizzazzjoni għat-tqegħid fis-suq fl-UE.
English: Route of Administration
Maltese: Daqs talpakkett
English: Immediate Packaging Pack size
Maltese: Mnejn għandu jingħata Il-pakkett li jmiss mal-prodott
English: Grades 3&4
Maltese: Grad 3&4
English: Antidepressants Trazodone
Maltese: Antidepressanti Trazodone
English: ITT (NC = F) Observed data LOCF
Maltese: ITT (NC = F) Informazzjoni osservata LOCF
English: • Pancreatitis.
Maltese: • Pankrejatite.
English: AUC24 (mg.hr/L) Arithmetic mean ± SD
Maltese: AUC24 (mg.hr/L) Medja aritmetika ± SD
English: • A severe form of rash (erythema multiforme).
Maltese: • Forma severa ta' raxx (eritema multiforme).
English: • Blue 5 gram (5g) scoop.
Maltese: • Kuċċarina blu ta' 5 grammi (5g).
English: AG1343-524 20 (19-28) mg/kg TID
Maltese: AG1343-524 20 (19-28) mg/kg
English: Ultrasensitive
Maltese: Ultrasensittiva
English: Endothelin receptor antagonists Bosentan
Maltese: Antagonisti tar-riċettur ta' endothelin Bosentan
English: • Infection.
Maltese: • Infezzjoni.
English: HMG-CoA reductase inhibitors (Statins)
Maltese: Inibituri ta' HMG-CoA reductatse (Statins)
English: Viracept TID (%)
Maltese: Viracept BID (%) Viracept TID (%) 95 % CI
English: (E132), as powder, hypromellose and glycerol triacetate.
Maltese: (E132), bħala trab, hypromellose u glycerol triacetate.
English: Sensitive
Maltese: Sensittiva
English: • Rifampicin (for tuberculosis (TB))
Maltese: • Rifampicin (għat-tuberkulosi (TB)
English: H1 Receptor Antagonists, 5-HT Agonists Terfenadine, astemizole, cisapride
Maltese: Antagonisti tar-riċettur H1, agonisti 5-HT Terfenadine, astemizole, cisapride
English: • Fluticasone (for hay fever)
Maltese: • Fluticasone (għal hay fever)
English: • Fluoxetine, paroxetine, imipramine, amitriptyline or trazodone (for depression)
Maltese: • Fluoxetine, paroxetine, imipramine, amitriptyline jew trazodone (għad-depressjoni)
English: The EC95 (95 % effective concentration) of nelfinavir ranged from 7 to 111 nM (mean of 58 nM).
Maltese: L-EC95 (95 % konċentrazzjoni effettiva) ta' nelfinavir varjat minn 7 sa 111 nM (medja ta' 58 nM).
English: M8 metabolite Cmin ↓ 75%
Maltese: Cmin tal-metabolit M8 ↓ 75 %
English: Calcium silicate,
Maltese: Calcium silicate , Crospovidone,
English: The absolute bioavailability of VIRACEPT has not been determined.
Maltese: Il-biodisponibilità assoluta ta' VIRACEPT ma ġietx determinata.
English: • Oral contraceptives (the pill).
Maltese: • Kontraċettivi orali (il-pillola kontraċettiva).
English: Date of latest renewal: 23 January 2008
Maltese: Data ta' l-aħħar tiġdid: 23 ta' Jannar 2008
English: Delavirdine AUC ↓ 31 % Nelfinavir AUC ↑ 107 %
Maltese: AUC ta' delavirdine ↓ 31 % AUC ta' nelfinavir ↑ 107 %
English: Also contains E95, sucrose palmitate, potassium.
Maltese: Fih ukoll E951, sucrose palmitate, potassium.
English: 6.2 Incompatibilities
Maltese: .2 Inkompatabilitajiet
English: Musculoskeletal and connective tissue disorders:
Maltese: Disturbi muskolu-skeltrali u tal-connective tissue:
English: • The other ingredients are calcium silicate, crospovidone, magnesium stearate, indigo carmine
Maltese: • Is-sustanzi l-oħra huma calcium silicate, crospovidone, magnesium stearate, indigo carmine
English: 7.5 to 8.5 kg
Maltese: 7.5 sa 8.5 kg
English: Distribution: Nelfinavir in serum is extensively protein-bound (≥ 98 %).
Maltese: Nelfinavir fis-serum huwa marbut b'mod estensiv mal-proteini (≥ 98 %).
English: Nelfinavir is primarily metabolised via the cytochrome P450 isoenzymes CYP3A4 and CYP2C19 (see section 5.2).
Maltese: Nelfinavir huwa metabolizzat primarjament permeżż ta' l-isoenzimi taċ-ċitokromju P450, CYP3A4 u CYP2C19 (ara sezzjoni 5.2).
English: Nelfinavir AUC ↑ 83%
Maltese: AUC ta' nelfinavir ↑ 83 %
English: - Contains potassium: 50.0 mg of dibasic potassium phosphate corresponding to 22.5 mg of See section 4.4
Maltese: - Fiħ potassium: 50.0 mg ta' dibasic potassium phosphate li jikkorrispondi għal 22.5 mg ta' Ara sezzjoni 4.4
English: Oral powder.
Maltese: Trab orali.
English: 144 g Oral powder
Maltese: 144 g ta' Trab orali
English: Amprenavir AUC ↔ Amprenavir Cmin ↑ 189 % Nelfinavir AUC ↔
Maltese: Cmin ta' amprenavir ↑ 189 % AUC ta' Nelfinavir ↔
English: VIRACEPT oral powder also contains sucrose.
Maltese: VIRACEPT trab orali fiħ ukoll sucrose.
English: Non-nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs) Efavirenz 600 mg QD (Nelfinavir 750 mg TID)
Maltese: Inibituri Analogi Mhux Nucleoside ta' Reverse Transcriptase (NNRTIs) Efavirenz 600 mg QD (Nelfinavir 750 mg TID)
English: INFORMATION IN BRAILLE viracept 250 mg
Maltese: INFORMAZZJONI BIL-BRAILLE viracept 250 mg